Fundamentally New Therapeutic for the Treatment of Acinetobacter Baumannii Wound Infections

ConjuGon has developed a fundamentally new antibacterial technology that is able to kill antibiotic-resistant bacteria. The technology uses harmless bacteria to transfer DNA into targeted, pathogenic bacteria. This DNA is expressed in the target to quickly kill them. We have developed a therapeutic based on this technology that can effectively kill Gram negative bacterial pathogens. In Phase 1 of this project, we demonstrated the therapeutic's ability to kill a large number of clinical isolates of Acinetobacer baumannii, a pathogen that is infecting large numbers of wounded soldiers. In Phase 2 of this project, we will perform preclinical toxicology and efficacy tests necessary to file an Investigational New Drug Application with the Food and Drug Administration. This is necessary before the therapeutic may be tested on humans.